Novel immunomodulatory agents have considerably improved the treatment of multiple sclerosis in recent years, but inhibiting disease progression remains a central challenge. This article describes how advances in the understanding of the immunopathogenesis of multiple sclerosis have identified a range of novel targets for intervention and potential therapeutic agents acting at various steps in the pathogenic cascade, including different aspects of T-cell and B-cell function and neuroprotective strategies.
- Rocio S. Lopez-Diego
- Howard L. Weiner